Forest To Launch Alcoholism Treatment Campral By Year-End
This article was originally published in The Pink Sheet Daily
The company will use the portion of its antidepressant sales force already detailing alcohol treatment facilities to market the drug. Forest plans to work with psychiatrists and treatment groups to develop an alcoholism management program that includes Campral.
You may also be interested in...
FDA clears acamprosate as alcoholism maintenance therapy. The drug may not be effective in patients who are actively drinking at the start of treatment, the agency says.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products